 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease. (Pubmed Central) - Dec 6, 2024
Ropsacitinib demonstrated superiority over placebo in the management of plaque psoriasis. Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib.
- || brepocitinib topical cream (PF-06700841 topical) / Priovant Therap, brepocitinib (PF-06700841) / Priovant Therap
PK/PD data, Journal: Pharmacokinetic Profile of Brepocitinib with Topical Administration in Atopic Dermatitis and Psoriasis Populations: Strategy to Inform Clinical Trial Design in Adult and Pediatric Populations. (Pubmed Central) - Mar 23, 2024
Brepocitinib and Ropsacitinib had more side effects than Deucravacitinib. The relationship between the amount of active drug applied and brepocitinib systemic CTrough, described by LMER, may inform the development strategy for dose optimization in the brepocitinib topical program.
- Risk-Benefit Appraisal of Systemic JAK Inhibitors for Alopecia Areata: A Comprehensive Meta-Analysis Assessing Safety and Adverse Effects () - Nov 6, 2023 - Abstract #ISDS2023ISDS_235;
The OR for common side effects, notably URI, showed an above 6-fold increase compared to placebos. Nevertheless, the data underscores a restrained risk for severe adverse events.
- | brepocitinib topical cream (PF-06700841 topical) / Priovant Therap, brepocitinib (PF-06700841) / Priovant Therap
Journal: Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis? (Pubmed Central) - Jul 10, 2023
Nevertheless, the data underscores a restrained risk for severe adverse events. No abstract available
- Adverse events in patients treated with Jak-inhibitors for alopecia areata: a systematic review () - Jul 3, 2023 - Abstract #WCD2023WCD_5751;
The AEs in AA patients receiving JAK-I are mostly mild and self-limited and predominantly consist of an increased risk of infections and laboratory abnormalities. No fatal outcomes or thromboembolism events have been reported
- || brepocitinib topical cream (PF-06700841 topical) / Priovant Therap
P2b data, Journal: Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study. (Pubmed Central) - Mar 28, 2023
P2b
No fatal outcomes or thromboembolism events have been reported Topical brepocitinib was well-tolerated but did not result in statistically significant changes vs. vehicle when administered at the doses evaluated to treat signs and symptoms of mild-to-moderate PsO.
- | brepocitinib topical cream (PF-06700841 topical) / Priovant Therap
Journal: How will brepocitinib cream compare with established treatments for mild-to-moderate eczema? (Pubmed Central) - Oct 7, 2022
Topical brepocitinib was well-tolerated but did not result in statistically significant changes vs. vehicle when administered at the doses evaluated to treat signs and symptoms of mild-to-moderate PsO. No abstract available
- || Retrospective data, Review: The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies. (Pubmed Central) - Sep 14, 2022
Due to the high recurrence rate after withdrawal of JAK inhibitors, continuous treatment should be considered to maintain efficacy. Systematic Review Registration: PROSPERO: CRD 42022303007.
- || brepocitinib topical cream (PF-06700841 topical) / Priovant Therap
P2b data, Journal: Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study. (Pubmed Central) - Aug 25, 2022
P2b
Topical brepocitinib is effective and well tolerated in participants with mild-to-moderate AD. This trial is registered with clinicaltrials.gov and with EudraCT (2018-003050-24).
- || Review, Journal: Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis. (Pubmed Central) - Apr 15, 2022
Selective, allosteric inhibition of TYK2 signaling may reduce the potential for toxicities associated with pan-JAK inhibitors. This article reviews JAK-STAT and TYK2 signaling, and the efficacy and safety of JAK inhibitors in psoriasis to date, focusing specifically on TYK2 inhibitors.
- || Enbrel (etanercept) / Pfizer, Amgen
Clinical, Review: A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis. (Pubmed Central) - Mar 15, 2022
Nine different drugs administered through various routes were identified (systemic: peficitinib, baricitinib, solcitinib, itacitinib, abrocitinib, deucravacitinib, and brepocitinib; topical: ruxolitinib; and both: tofacitinib)...Only tofacitinib and deucravacitinib have undergone phase III clinical trials, being the only ones tested with active comparators etanercept and apremilast, respectively...Psoriasis treatment is currently symptomatic and could potentially present a significant risk of toxicity. Therefore, the design of principal efficacy outcome measures considering the impact of the outcome on quality of life and a drug assessment methodology aimed at improving safety would probably strengthen the evidence and decision-making process.
- | brepocitinib topical cream (PF-06700841 topical) / Pfizer
Journal: New Topical Therapies for Psoriasis. (Pubmed Central) - Feb 17, 2022
Ongoing preclinical studies involving interleukin-2 inhibition, RNA modulators and amygdalin analogues may lead to forthcoming clinical trials. New topical drugs are successfully emerging and future research comparing them to classical options will dictate their clinical role in the treatment of psoriasis.
- |||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Trial completion, Enrollment change: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - May 21, 2021
P2b, N=344, Completed, Sponsor: Pfizer
New topical drugs are successfully emerging and future research comparing them to classical options will dictate their clinical role in the treatment of psoriasis. Recruiting --> Completed | N=240 --> 344
- | Journal: JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. (Pubmed Central) - Dec 18, 2020
Results of studies with TYK2 inhibitors will be important in assessing the clinical efficacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis. This article reviews current data on the impact of JAK inhibitors in the treatment of adult patients with moderate-to-severe psoriasis.
- brepocitinib topical cream (PF-06700841 topical) / Pfizer, brepocitinib (PF-06700841) / Pfizer
[VIRTUAL] A Phase 2b study to evaluate the efficacy and safety of the topical TYK2/JAK1 inhibitor brepocitinib for mild-to-moderate atopic dermatitis (Alibert) - Oct 20, 2020 - Abstract #EADV2020EADV_1080;
- |||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Enrollment open: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Jul 17, 2020
P2b, N=240, Recruiting, Sponsor: Pfizer
This article reviews current data on the impact of JAK inhibitors in the treatment of adult patients with moderate-to-severe psoriasis. Active, not recruiting --> Recruiting
- ||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Enrollment closed: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Jun 18, 2020
P2b, N=294, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Trial completion: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (clinicaltrials.gov) - Jun 9, 2020
P2b, N=295, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Completed
- || brepocitinib topical cream (PF-06700841 topical) / Pfizer
Trial completion date, Trial primary completion date: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Apr 27, 2020
P2b, N=240, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Trial completion date: May 2020 --> Apr 2021 | Trial primary completion date: May 2020 --> Apr 2021
- |||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Enrollment open: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (clinicaltrials.gov) - May 29, 2019
P2b, N=280, Recruiting, Sponsor: Pfizer
Trial completion date: May 2020 --> Apr 2021 | Trial primary completion date: May 2020 --> Apr 2021 Not yet recruiting --> Recruiting
- || brepocitinib topical cream (PF-06700841 topical) / Priovant Therap
Trial completion: Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants (clinicaltrials.gov) - May 23, 2019
P1, N=20, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
Enrollment open: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Apr 25, 2019
P2b, N=240, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- || brepocitinib topical cream (PF-06700841 topical) / Priovant Therap
New P1 trial: Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy Participants (clinicaltrials.gov) - Apr 15, 2019
P1, N=20, Recruiting, Sponsor: Pfizer
- |||||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
New P2b trial: Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis (clinicaltrials.gov) - Apr 3, 2019
P2b, N=280, Not yet recruiting, Sponsor: Pfizer
- |||||| brepocitinib topical cream (PF-06700841 topical) / Pfizer
New P2b trial: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis (clinicaltrials.gov) - Feb 21, 2019
P2b, N=240, Not yet recruiting, Sponsor: Pfizer